Navigation Links
Medicinal chemist wins inaugural De Burgh Fellowship
Date:11/11/2010

Medicinal chemist Dr Guillaume Lessene has been awarded the Walter and Eliza Hall Institute's inaugural de Burgh Fellowship at the institute's annual general meeting in Melbourne, Australia.

The $AUD150,000 de Burgh Fellowship honours the role Professor Patrick de Burgh played in shaping the Walter and Eliza Hall Institute. It was established this year following the death of Professor de Burgh in August at the age of 94.

It was in Professor de Burgh's laboratory at the University of Sydney that institute legends Professor Donald Metcalf, Professor Jacques Miller and Sir Gustav Nossal obtained their first taste of research.

Professor de Burgh was a Bosch Professor or Bacteriology at the University of Sydney and worked on the pathogenesis of infectious disease.

Dr Lessene said it was a great honour to be named the de Burgh Fellow. "The fact the fellowship acknowledges translational research is really important that is what I do every day and it's great that these activities are supported by the fellowship and the institute," Dr Lessene said.

Dr Lessene translates research findings from the institute into the discovery and development of new drugs. His main focus is cancer research and Dr Lessene is currently working on developing inhibitors to the pro-survival Bcl-2 proteins that are involved in programmed cell death, for treatment of several types of cancer. He is also involved in projects looking at other cancer targets, such as tyrosine kinases, and non-cancer targets involved in conditions such as Alzheimer's disease.

"We work in multidisciplinary teams in constant interaction with biologists to create small molecules that will interact with or modulate recognised cell signaling pathways or targets involved in disease, with the aim of treating or curing that disease," Dr Lessene said.

"The very high standing of the research at the institute is a key element in the success of our program. The Chemical Biology division of which I am part is there to take the next step, bringing these biological discoveries from the laboratory and translating them into molecules that have the right biological activities and properties to reach clinical trials and potentially become a new drug."

Institute director Professor Doug Hilton congratulated Dr Lessene and said the institute and the Australian community owed Professor de Burgh a great debt.

"One could only imagine the shape of Australian medical research today had Professor de Burgh provided a humdrum rather than an inspiring environment," Professor Hilton said.

"The De Burgh Fellowship is awarded to a scientist with an outstanding record of research or research translation, who collaborates productively with other members of the faculty, and who is likely to make a major contribution to the institute in the long term. Guillaume meets all these criteria with aplomb."


'/>"/>

Contact: Penny Fannin
fannin@wehi.edu.au
61-393-452-345
Walter and Eliza Hall Institute
Source:Eurekalert  

Related medicine news :

1. Medicinal cannabis review highlights dilemmas facing health care professionals
2. Pfizer joins open-access medicinal chemistry public-private collaboration
3. St. Johns wort collection mined for its medicinal value
4. MIT chemists engineer plants to produce new drugs
5. 2010 Chemistry Nobel laureate Ei-ichi Negishi leads C&EN webinar
6. Biochemist studies DNA repair with $787,000 in grants
7. MIT moves toward greener chemistry
8. Basque researchers apply chemistry to restoration of paintings and dating of signatures
9. Subtyping breast cancer by immunohistochemistry to investigate survival terms
10. Tastier MRE: Chemistry gives battlefield chow a gourmet flare
11. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Medicinal chemist wins inaugural De Burgh Fellowship
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, 2017 , ... ... natural chai teas, announced its products are now available for purchase on RevNutrition.com, a ... ancient form of tea first produced and popularized in ancient India and Siam. It ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... healthcare compliance and credentialing solutions, today announced that Kyle Allain has joined the ... Cactus Provider Management sales and operations, including provider, payor and managed care solutions. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research ... of this type of healthcare model in the diagnosis and treatment of brain ...
(Date:4/24/2017)... IL (PRWEB) , ... April 24, 2017 , ... Rod ... the Senior Housing News website. , Rod has been at the forefront of Gardant ... company’s culture. As CEO, Rod has overseen the opening of more than 40 new ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for ... The good news for single women is that she put all the words in ... April 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: